The HudsonAlpha Institute for Biotechnology and amaxa AG have entered into a collaborative agreement whereby the Institute will utilize amaxa Nucleofector^® Technology as a core technology in certain research projects. One of the earliest projects will focus on a broad study across the NCI-60 cell line panel.  This technology will allow the HudsonAlpha Institute researchers to develop reproducible, non-viral based, optimized transfection protocols for the cell lines included in the National Cancer Institute’s drug discovery panel. This will allow the study of gene control in the most extensively studied cell lines in the world.

“One of our goals is to develop high-throughput research tools that focus on why disease occurs and to rapidly apply this knowledge to help patients. To that end we recognize the need to understand cellular changes across many cell types. amaxa’s Nucleofector^® 96-well Shuttle^® System is an important tool that will help provide the necessary capability,” said Jim Hudson, president of the HudsonAlpha Institute.

“The HudsonAlpha Institute’s comprehensive, high-throughput approach to research makes it an ideal collaborative partner for amaxa’s technology.  It is our goal to enable our customers to genetically manipulate whatever cell types they consider the best experimental model. This collaboration is a natural outcome of aligned objectives,” said Rainer Christine, co-founder and CEO, amaxa.